Clinical Trials Logo

Opioid-Induced Bowel Dysfunction clinical trials

View clinical trials related to Opioid-Induced Bowel Dysfunction.

Filter by:
  • None
  • Page 1

NCT ID: NCT06385561 Completed - Constipation Clinical Trials

The Influence of Tramadol on Opioid-induced Bowel Dysfunction

Start date: August 11, 2022
Phase: Phase 2
Study type: Interventional

Tramadol is a weak opioid and widely used to treat moderate to severe pain. Stronger opioids are known to inhibit gastrointestinal motility and secretion, however the effects of tramadol on gastrointestinal function remains less understood. The aim of this study was to determine to what degree tramadol causes opioid-induced bowel dysfunction by using an objective design to explore gastrointestinal transit, motility pattern, secretion, and colonic volume, in a group of healthy male volunteers.

NCT ID: NCT06334198 Recruiting - Constipation Clinical Trials

The Effect of Naldemedine on Opioid-induced Bowel Dysfunction

Start date: March 12, 2024
Phase: Phase 2
Study type: Interventional

Opioid-induced bowel dysfunction is a frequent condition during opioid therapy for chronic pain. Indeed, up to 90% of people on opioid treated patients experience constipation. Standard laxative treatment is often ineffective in opioid-induced constipation, but peripheral acting mu-receptor antagonists (PAMORAs) have the potential to block the effects of opioids in the gastrointestinal tract while preserving the central analgesic effect. In this study, we will investigated the effects of Naldemedine in preventing the development of opioid-induced bowel dysfunction and constipation during treatment with tramadol

NCT ID: NCT04876508 Recruiting - Clinical trials for Opioid-induced Bowel Dysfunction

The Efficacy of Acupressure in Managing Opioid-induced Constipation

Start date: August 1, 2020
Phase: N/A
Study type: Interventional

In a randomized controlled study to evaluate the effect of acupressure application on opioid-related constipation, the Patient Identification Form, Defecation Diary, Visual Analog Scale and Constipation Quality of Life Scale will be applied after obtaining written informed consent from the patients. Patients in the experimental group will be given acupressure once a day for 7 consecutive days. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the patients are in supine position, pressure will be applied to each acupressure point around the navel, respectively, Zhongwan (CV12), Guanyuan (CV4) and Tianshu (ST25) for 2 minutes for a total of 6 minutes. No attempt will be made to the control group. All patients will be followed for a total of 4 weeks and the Defecation Diary and Visual Comparison Scale will be applied weekly. 4. Constipation Quality of Life Scale will be applied again at the end of the week. The study was planned to examine the effect of acupressure on opioid-related constipation.

NCT ID: NCT01298219 Completed - Clinical trials for Opioid-induced Bowel Dysfunction

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

Start date: December 2010
Phase: Phase 3
Study type: Interventional

The primary purpose of the study is to evaluate the efficacy and safety of lubiprostone administration in subjects with Opioid-induced Bowel Dysfunction.

NCT ID: NCT01122030 Completed - Clinical trials for Opioid Induced Bowel Dysfunction

Study to Evaluate the Safety and Efficacy of S-297995 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

Start date: April 2010
Phase: Phase 2
Study type: Interventional

Study consists of 6 treatment cohorts of 12 subjects with chronic pain, opioid-induced bowel dysfunction, and opioid physical dependence. Total duration of treatment for each subject will be up to 28 days. Each subject will receive a single dose of study drug, administered orally in the morning of Day 15 under fasted conditions. Cohort 1: 0.1 mg of S-297995 or placebo. Cohort 2: 0.3 mg of S-297995 or placebo. Cohort 3: 1 mg of S-297995 or placebo. Cohort 4: 3 mg of S-297995 or placebo. Cohort 5: 0.03 mg of S-297995 or placebo. Cohort 6: 0.01 mg of S-297995 or placebo. The primary objective of the study is to evaluate the safety of single doses of oral S-297995 in subjects physically dependent on opioids

NCT ID: NCT00620061 Completed - Clinical trials for Opioid-Induced Bowel Dysfunction

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

Start date: December 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in participants with opioid-induced bowel dysfunction.

NCT ID: NCT00597428 Completed - Clinical trials for Opioid-Induced Bowel Dysfunction

Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone

OPAL
Start date: August 2007
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the efficacy and safety of lubiprostone administration in patients with opioid-induced bowel dysfunction (OBD).

NCT ID: NCT00595946 Completed - Clinical trials for Opioid-Induced Bowel Dysfunction

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

OPAL
Start date: August 2007
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the efficacy and safety of lubiprostone administration in patients with Opioid-induced Bowel Dysfunction.